Company Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells.
The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer.
Marker Therapeutics is headquartered in Houston, Texas.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Juan F. Vera M.D. |
Contact Details
Address: 4551 Kennedy Commerce Dr. Houston, Texas 77032 United States | |
| Phone | (713) 400-6400 |
| Website | markertherapeutics.com |
Stock Details
| Ticker Symbol | MRKR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001094038 |
| CUSIP Number | 57055L107 |
| ISIN Number | US57055L2060 |
| Employer ID | 88-0277072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Juan F. Vera M.D. | Co-Founder, Chief Executive Officer, President, Treasurer and Director |
| Elizabeth Donnelly | Director of Administration |
| Edmund Cheung | Vice President of Human Resources |
| Dr. Nadia Agopyan Ph.D. | Senior Vice President of Regulatory Affairs |
| Dr. Monic Stuart M.D. | Chief Medical Officer |
| Patricia Allison | Head of Clinical Operations |
| Michael J. Loiacono | Secretary |
| Dr. Robert Z. Florkiewicz Sr. | Senior Director of Molecular Biology and Virology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 8-K | Current Report |
| Jan 8, 2024 | 8-K | Current Report |
| Dec 11, 2023 | 8-K | Current Report |
| Nov 20, 2023 | 8-K | Current Report |